Showing results (201-210 of 205) with videos related to
Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 205 results.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.Pageof 21